Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Over half of refractory AML patients responded to combo

Advani A et al. ASH 2017, Abstract 150.

Key clinical point: MEC plus ixazomib is well tolerated and effective in relapsed/refractory AML.

Major finding: The overall response rate was 53%.

Study details: A phase 1 trial involving 30 patients.

Disclosures: Dr. Advani reported receiving research funding from Takeda/Millenium, and serving as a consultant for Pfizer.

Source: Advani A et al. ASH 2017, Abstract 150.

Read the full article.

Citation:

Advani A et al. ASH 2017, Abstract 150.

This Week's Must Reads

Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.

Levofloxacin prophylaxis in ALL, AML , Alexander S, et al. JAMA. 2018;320(10):995-1004

Genetic markers signal poor prognosis in MCL, Obr A et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 23. doi: 10.1016/j.clml.2018.07.282

Disparities in ALL treatment toxicity, Taylor OA et al. Clin Cancer Res. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-0939

Leukemia risk after maternal contraception use, Hargreave M et al. Lancet Oncol. 2018 Sep 6. doi: 10.1016/S1470-2045(18)30479-0

Must Reads in AML

Levofloxacin prophylaxis in ALL, AML , Alexander S, et al. JAMA. 2018;320(10):995-1004

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Vadastuximab talirine improves AML remission rates, Fathi AT et al. Blood. 2018 Jul 25. doi: 10.1182/blood-2018-03-841171.

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release

Second filgrastim biosimilar approved by FDA, U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi), Pfizer press release